William Conte, MD
Neurology · Merrillville, INNPI 1467794271
Payments from drug & device makers
Across 2,656 payments — averaging $653.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$464K
- EMD Serono, Inc.$313K
- Sanofi$188K
- Biogen$187K
- TG Therapeutics, Inc.$127K
- AstraZeneca$90K
- plus $365K from 54 others
Across 11 payments — averaging $878.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$8K
- Sanofi US Services Inc.$1K
What the payments were for
- Consulting fees$150,19212%
- Speaking & faculty fees$933,59376%
- Travel & lodging$84,9887%
- Food & beverage$55,4445%
- Education$5600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,735,461 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MavencladCladribine | 27 | $2,064,534 |
| VumerityDiroximel Fumarate | 56 | $616,048 |
| Kesimpta PenOfatumumab | 43 | $380,359 |
| AubagioTeriflunomide | 27 | $250,299 |
| MayzentSiponimod | 24 | $231,680 |
| AustedoDeutetrabenazine | 11 | $134,046 |
| Teriflunomide | 84 | $127,460 |
| IngrezzaValbenazine Tosylate | 12 | $116,679 |
| CopaxoneGlatiramer Acetate | 12 | $84,001 |
| Austedo XrDeutetrabenazine | 11 | $64,836 |
| Emgality PenGalcanezumab-Gnlm | 90 | $62,671 |
| NuedextaDextromethorphan Hbr/Quinidine | 36 | $56,340 |
| Dalfampridine ErDalfampridine | 114 | $54,270 |
| Aimovig AutoinjectorErenumab-Aooe | 51 | $37,730 |
| XcopriCenobamate | 15 | $29,646 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Mavenclad | $313,346 | $2,064,53427 claims |
| BiogenVumerity | $187,081 | $616,04856 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Copaxone, Austedo Xr | $826 | $282,88334 claims |
| SanofiAubagio | $188,275 | $250,29927 claims |
| NovartisMayzent | $463,817 | $231,68024 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $370 | $116,67912 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $65 | $56,34036 claims |
| SK Life Science, Inc.Xcopri | $283 | $29,64615 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $59 | $28,85516 claims |
| AbbVieQulipta | $10,379 | $28,81520 claims |
| PfizerNurtec Odt | $381 | $18,64914 claims |
| UCB, Inc.Briviact | $299 | $16,97012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 neurology providers in Indiana.
Other neurology in Merrillville
- Richard CristeaMerrillville$30K
- Kristi GeorgeIndianapolis$10.8M
- Craig HerrmanIndianapolis$7.8M
- Martin FarlowIndianapolis$4.8M
- Jared BroschIndianapolis$4.7M
- Ajay GuptaFort Wayne$2.5M
- Christopher WilsonAvon$2M
- Alexandru BarboiIndianapolis$1.9M
- James StevensFort Wayne$1.5M
- Kathryn NevelIndianapolis$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.